SHANGHAI – Two-year-old Engine Biosciences Pte Ltd., a startup with an artificial intelligence (AI) platform approach to drug discovery, recently received a $10 million endorsement from Chinese and U.S. investors. Engine is one of a growing number of AI-first, data-driven biotechs that are plying the latest advances in machine learning to the complex task of understanding human biology to find new medicines.